drugset / Trial / NCT01090817
An Australian Study of Mesenchymal Stromal Cells for Crohn's Disease
Phase 2
Completed
21 enrolled
R.P.Herrmann
Concord Hospital · collabSir Charles Gairdner Hospital · collabThe Alfred · collabThe Queen Elizabeth Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Despite the advent of newer biologic therapies such as infliximab for Crohn's disease, a form of autoimmune inflammatory bowel disease, a proportion of patients are refractory to such therapy and require surgery. The hypothesis is that mesenchymal stromal cell therapy using third party human cultured cells will be safe and effective
Timeline
- Start
- 2010-01
- Primary completion
- 2014-06
- Completion
- 2015-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mesenchymal stem cells | Cell therapy | 2e+06 cells/kg | Intravenous |